2022年10月13日

东部夏令时2022年10月13日08:30马萨诸塞州剑桥生物制药公司LifeMine Therapeutics公司今天宣布任命Jennifer Jarrett为其董事会成员，该公司通过从生物圈中挖掘基因编码小分子(gem)来重新发明药物。Jarrett女士是医疗保健和技术行业的一位有成就的高管，在运营、资本市场、金融、企业发展和战略方面拥有专业知识。LifeMine的联合创始人、总裁兼首席执行官Gregory Verdine博士说:“LifeMine不断吸引公司内部和董事会的杰出人才。”“任永力拥有丰富的运营、财务和公司建设经验，这将补充我们董事会现有的能力。她的专业知识将有助于我们进一步发展和扩大该组织，重新发明小分子药物，并开发肿瘤和免疫调节方面的高影响疗法。”Jarrett女士目前是Arcus Biosciences的首席运营官和董事会成员，这是一家临床阶段的生物制药公司，专注于为癌症患者开发分化分子和联合疗法。她目前担任Syndax Pharmaceuticals和SMART(非营利组织)的董事会成员，此前担任Arena Pharmaceuticals和Audentes Therapeutics的董事会成员。Jarrett女士此前曾担任Uber的企业发展和资本市场副总裁，以及Medivation的首席财务官。加入Medivation之前，Jarrett女士在投资银行工作了20年，最近是在花旗集团(Citigroup)，在那里她负责公司西海岸生命科学投资银行业务。在此之前，她在瑞士信贷(Credit Suisse)和Donaldson, Lufkin & Jenrette工作。 Ms. Jarrett holds a B.A. in economics from Dartmouth College and an MBA from Stanford University Graduate School of Business. About LifeMine Therapeutics LifeMine Therapeutics is reinventing drug discovery by mining genetically-encoded small molecules (GEMs) from the biosphere. Through its proprietary, evolutionarily-derived genomic drug discovery platform, LifeMine aims to bring unparalleled speed, predictability and scalability to small molecule drug discovery. LifeMine has discovered, in genomic space, hundreds of potentially high-impact drug candidates relevant to targets across all major disease areas, and has an initial focus on advancing highly impactful precision medicines in oncology and immune modulation. The company was founded in 2017 by renowned entrepreneur/scientists Gregory Verdine, Ph.D., and Richard Klausner, M.D., and entrepreneur/company-builder WeiQing Zhou. Headquartered in Cambridge, Mass., with offices in Gloucester Harbor, Mass. and Basel, Switzerland, LifeMine has raised more than $295 million from leading life science investors. For additional information, please visit www.lifeminetx.com . Contacts